Gerresheimer's AGM Passes Without Drama, But the €1.5bn Portfolio Pivot Carries the Real Weight

Gerresheimer shareholders approve all resolutions; divestments of plastics units to Apax proceed, with core pharma packaging margins improving.

The glassmaker's annual meeting on Tuesday delivered exactly what a company in transition needed: unanimity. With 41.59 percent of share capital represented, shareholders waved through every resolution on the table, handing fresh mandates to supervisory board members Rainer Beaujean, Markus Sieger and Eva van Pelt while re-electing Klaus Röhrig. Sieger stepped straight into the chairmanship, replacing the outgoing trio of Axel Herberg, Andrea Abt and Annette Köhler. Executive board members Uwe Röhrhoff, Wolf Lehmann and Achim Schalk received their discharge for 2025, and KPMG was confirmed as auditor for 2026.

For a company that has spent recent months navigating leadership upheaval and softening metrics, the frictionless vote was itself a statement. Yet the more consequential news had already landed back in late July, when Gerresheimer struck an agreement with Apax Funds to offload Centor US Holding alongside its global plastic primary packaging (PPP) operations. The combined enterprise value: roughly €1.5 billion, covering units that generated around €570 million in sales and employed approximately 2,400 people.

The transaction timeline is staggered. Centor is expected to close by the end of the current fiscal year, while the PPP disposal is slated for the first half of fiscal 2027. Until both deals complete, the company's margin trajectory remains partly hostage to timing — a point investors would do well to weigh against management's upbeat guidance.

The strategic logic, however, is hard to fault. Shedding the lower-margin plastics business sharpens the group's focus on pharmaceutical packaging and delivery systems, where the first-quarter numbers show tangible momentum. Containment & Delivery Systems lifted revenue to €296 million, with adjusted EBITDA margin climbing to 20.6 percent from 18.5 percent in the year-earlier period. That improvement is the clearest evidence yet that the portfolio surgery is aimed at something more than balance-sheet relief.

Group-wide, the picture is more textured. Total revenue edged up to €524 million, but adjusted EBITDA slipped from €81 million to €66 million, dragging the margin down to 12.6 percent from 15.7 percent. The brighter spot came from free cash flow, which improved markedly from minus €141 million to minus €32 million. Management reaffirmed its full-year forecast and pointed to a stronger second half — a promise that will be tested when the final Q1 figures land in September, followed by the half-year report in November.

The leadership question adds another layer of suspense. Uwe Röhrhoff's early departure on his own request left the CEO seat vacant, with Lehmann and Schalk jointly covering the role in the interim. A permanent appointment remains open, meaning the operational engine is running but the strategic helm is not yet permanently manned.

Meanwhile, the company continues to invest in its retained core. A new glass furnace in Zhenjiang Dagang, China, came online in July, expanding primary packaging capacity — a signal that this is a restructuring story with growth ambitions attached, not a retreat into retrenchment.

The share price has been quietly recovering, trading around €27.90, roughly 5.4 percent above its level a week earlier. That modest bounce suggests the market is absorbing recent headlines without alarm. Still, the stock sits about 36 percent below where it stood twelve months ago, and the current market capitalization of approximately €928 million underscores how much ground has been lost during a stretch that included a plant closure, a revised outlook and now the leadership shuffle.

Analyst commentary has been conspicuously quiet — the most recent documented assessment dates back to May and offers little fresh perspective on the current setup.

What matters now is execution. The margin gains in the core business must prove durable across coming quarters, and the divestment timetable needs to hold. If both fall into place, the strategic bet pays off. If not, the quiet confidence of Tuesday's meeting will look premature.